Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2024-06-11 00:00:00 ET · period of report 2024-06-08 · accession 0001415889-24-016416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-11 | 2024-06-10 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.79 | -975 | 34.6K | -3% | -$14.4K |
| D | 2024-06-11 | 2024-06-08 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | — | +1,893 | 35.5K | +6% | — |
| D | 2024-06-11 | 2024-06-08 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -1,893 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-10 | S | D | 975 | $14.79 | 34,564 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.675 to $14.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 2 | Common | Common Stock | 2024-06-08 | M | A | 1,893 | — | 35,539 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. |
| 3 | Derivative | Restricted Stock Units | 2024-06-08 | M | D | 1,893 | $0.00 | 0 | D | — · — to — | 1,893 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F5) The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024. |